ES2071288T3 - Vacuna mejorada de conjugado de polisacarido de meningococos. - Google Patents

Vacuna mejorada de conjugado de polisacarido de meningococos.

Info

Publication number
ES2071288T3
ES2071288T3 ES91900142T ES91900142T ES2071288T3 ES 2071288 T3 ES2071288 T3 ES 2071288T3 ES 91900142 T ES91900142 T ES 91900142T ES 91900142 T ES91900142 T ES 91900142T ES 2071288 T3 ES2071288 T3 ES 2071288T3
Authority
ES
Spain
Prior art keywords
reciprovals
coli
antibodies
modified
polysaccharide conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900142T
Other languages
English (en)
Spanish (es)
Inventor
Harold J Jennings
Francis Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Application granted granted Critical
Publication of ES2071288T3 publication Critical patent/ES2071288T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES91900142T 1989-12-14 1990-12-13 Vacuna mejorada de conjugado de polisacarido de meningococos. Expired - Lifetime ES2071288T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
ES2071288T3 true ES2071288T3 (es) 1995-06-16

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900142T Expired - Lifetime ES2071288T3 (es) 1989-12-14 1990-12-13 Vacuna mejorada de conjugado de polisacarido de meningococos.

Country Status (30)

Country Link
US (3) US5576002A (show.php)
EP (1) EP0504202B1 (show.php)
JP (1) JP2637845B2 (show.php)
KR (1) KR0158436B1 (show.php)
CN (4) CN1049223C (show.php)
AR (1) AR243934A1 (show.php)
AT (1) ATE121947T1 (show.php)
AU (1) AU641715B2 (show.php)
BR (1) BR9007917A (show.php)
CA (1) CA2071811C (show.php)
CZ (1) CZ283530B6 (show.php)
DE (1) DE69019164T2 (show.php)
DK (1) DK0504202T3 (show.php)
ES (1) ES2071288T3 (show.php)
FI (2) FI104539B (show.php)
HR (1) HRP920872A2 (show.php)
HU (2) HU9201966D0 (show.php)
IE (1) IE68414B1 (show.php)
IL (1) IL96676A (show.php)
IN (1) IN171747B (show.php)
NO (2) NO305275B1 (show.php)
NZ (1) NZ236471A (show.php)
PH (1) PH30305A (show.php)
PL (2) PL166659B1 (show.php)
RO (1) RO111416B1 (show.php)
RU (1) RU2105568C1 (show.php)
SI (1) SI20008B (show.php)
WO (1) WO1991008772A1 (show.php)
YU (1) YU24391A (show.php)
ZA (1) ZA9010065B (show.php)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
DE69019164T2 (de) * 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.
DK0667787T3 (da) * 1992-09-24 2001-10-29 Ca Nat Research Council Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
SI1090642T1 (sl) * 1995-06-07 2008-12-31 Glaxosmithkline Biolog Sa Vakcine, ki obsegajo konjugat polisaharidni antigen-nosilni protein in prosti nosilni protein
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
DK1007546T3 (da) 1997-08-27 2009-03-16 Novartis Vaccines & Diagnostic Molekylære mimetika af meningokok-B-epitoper
DE69841676D1 (de) 1997-12-23 2010-07-01 Baxter Healthcare Sa Verfahren zur extraktion und isolierung von bakteriellen hüllpolysacchariden zur verwendung als vakzine oder, an proteine gekoppelt, als konjugierte vakzine
RU2249463C2 (ru) * 1998-08-19 2005-04-10 Бакстер Хелфкэа С.А. Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
DE69941574D1 (de) * 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ535968A (en) * 2002-03-26 2006-08-31 Chiron S Modified saccharides having improved stability in water
AU2003239744B2 (en) * 2002-05-14 2008-07-03 Novartis Vaccines And Diagnostics S.R.L. Mucosal combination vaccines for bacterial meningitis
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
US20040219160A1 (en) * 2003-03-31 2004-11-04 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2735809T3 (es) * 2003-08-12 2019-12-20 Lipoxen Tech Limited Derivativos del ácido siálico para la derivatización y conjugación de proteínas
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
KR20070060069A (ko) * 2004-06-23 2007-06-12 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 다당류 유도체 및 면역반응의 유도에서의 용도
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN118021947A (zh) * 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
DE69019164T2 (de) * 1989-12-14 1995-09-07 National Research Council Of Canada, Ottawa, Ontario Verbessertes meningokokkale polysaccharidkonjugatvakzin.

Also Published As

Publication number Publication date
JP2637845B2 (ja) 1997-08-06
RO111416B1 (ro) 1996-10-31
CA2071811C (en) 2003-11-04
PH30305A (en) 1997-02-20
US5683699A (en) 1997-11-04
CN1036522C (zh) 1997-11-26
EP0504202B1 (en) 1995-05-03
CZ283530B6 (cs) 1998-04-15
CN1049223C (zh) 2000-02-09
CN1100656A (zh) 1995-03-29
CZ628490A3 (en) 1997-12-17
KR0158436B1 (ko) 1998-12-01
DK0504202T3 (da) 1995-10-02
YU24391A (sh) 1995-12-04
ATE121947T1 (de) 1995-05-15
IL96676A0 (en) 1991-09-16
AU6898791A (en) 1991-07-18
EP0504202A1 (en) 1992-09-23
BR9007917A (pt) 1992-10-20
JPH05505392A (ja) 1993-08-12
HRP920872A2 (en) 1997-06-30
IE68414B1 (en) 1996-06-12
AR243934A1 (es) 1993-09-30
CN1096516A (zh) 1994-12-21
PL166659B1 (pl) 1995-06-30
US5902586A (en) 1999-05-11
CN1100428A (zh) 1995-03-22
US5576002A (en) 1996-11-19
FI922737A0 (fi) 1992-06-12
RU2105568C1 (ru) 1998-02-27
IE904513A1 (en) 1991-06-19
PL288271A1 (en) 1991-12-16
DE69019164T2 (de) 1995-09-07
IN171747B (show.php) 1992-12-26
CN1036504C (zh) 1997-11-26
SI20008B (en) 2001-02-28
NO305275B1 (no) 1999-05-03
NO922316D0 (no) 1992-06-12
DE69019164D1 (de) 1995-06-08
HUT64480A (en) 1994-01-28
CN1072506C (zh) 2001-10-10
FI19991917A7 (fi) 1999-09-09
HU9201966D0 (en) 1992-10-28
NO922316L (no) 1992-08-14
NO973311D0 (no) 1997-07-17
NZ236471A (en) 1992-10-28
FI104539B (fi) 2000-02-29
NO973311L (no) 1992-08-14
CN1055541A (zh) 1991-10-23
FI19991917L (fi) 1999-09-09
PL166035B1 (pl) 1995-03-31
ZA9010065B (en) 1992-02-26
AU641715B2 (en) 1993-09-30
SI20008A (sl) 2000-02-29
HU218146B (hu) 2000-06-28
WO1991008772A1 (en) 1991-06-27
IL96676A (en) 1996-09-12
CA2071811A1 (en) 1991-06-15
NO307835B1 (no) 2000-06-05

Similar Documents

Publication Publication Date Title
ES2071288T3 (es) Vacuna mejorada de conjugado de polisacarido de meningococos.
Petrovsky Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity
Anderson et al. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.
JP3717511B2 (ja) サポニン−抗原複合物とその用途
DE69627652T2 (de) Verbesserte meningokokken polysaccharid-konjugat vakzine
ES2166097T3 (es) Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
DE69925187T2 (de) Antigenkonjugate von konservierten Lipooligosacchariden aus gram-negativen Bakterien
BR9510263A (pt) Novo derivado de ciclodextrina processo para sua preparação utilização dos mesmos composição terapêutica e adjuvante para vacinas
MC2178A1 (fr) Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
Cryz Jr et al. Safety and immunogenicity of a polyvalentKlebsiella capsular polysaccharide vaccine in humans
ES2171418T3 (es) Vacunas contra neisseria meningitidis del grupo c.
ATE120093T1 (de) Meningococcales klasse i-aussenmembranprotein- vakzin.
JPH08508978A (ja) Ｑｓ−２１を伴う、ガングリオシド‐ｋｌｈ複合体
NO840341L (no) Fremgangsmaate ved fremstilling av koplet h-influensa type b-vaksine
ES2145072T3 (es) Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
Sun et al. Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice
BR0112612A (pt) Misturas de polissacarìdeos sulfatados, processo de preparação das mesmas e composições farmacêuticas
FR2388563A1 (fr) Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires
FR2399252A1 (fr) Vaccin de masse moleculaire elevee contre la meningite a meningocoques du groupe c et procede pour sa preparation
ES2051909T3 (es) Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
DE69525638T2 (de) Synthese eines typhusimpfstoffes unter verwendung eines polysaccharids aus einer pflanze oder einer frucht
Trzewikoswki de Lima et al. Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged?
Cabral-Hipólito et al. Tannic acid exhibits adjuvant activity by enhancing humoral and cell-mediated immunity against BSA as a protein antigen
Habel Factors Influencing the Efficacy of Phenolized Rabies Vaccines: I. Strains of Fixed Virus
NO892015D0 (no) Fremgangsmaate for fremstilling av et legemiddel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504202

Country of ref document: ES